SELLAS Life Sciences (SLS) Amortizatization of Intangibles (2016 - 2026)
SELLAS Life Sciences (SLS) reported Amortizatization of Intangibles of $153000.0 for Q1 2026, up 4.08% year-over-year from $147000.0 in Q1 2025, and down 0.65% on a QoQ basis from $154000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 7 years of Amortizatization of Intangibles data on file, last reported at $153000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 4.08% year-over-year to $153000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $603000.0 (up 5.79% YoY) and the FY2025 annual result came in at $597000.0, up 6.42% from the prior year.
- Amortizatization of Intangibles fell to $153000.0 in Q1 2026 per SLS's latest filing, from $154000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $207000.0 in Q3 2022 and bottomed at $45000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $138000.0 (2024), against an average of $133117.6.
- Peak annual rise in Amortizatization of Intangibles reached 93.33% in 2023, while the deepest fall reached 41.06% in 2023.
- Tracing SLS's Amortizatization of Intangibles over 5 years: stood at $123000.0 in 2022, then rose by 4.07% to $128000.0 in 2023, then rose by 15.62% to $148000.0 in 2024, then advanced by 4.05% to $154000.0 in 2025, then declined by 0.65% to $153000.0 in 2026.
- Per Business Quant, the three latest SLS Amortizatization of Intangibles figures stand at $153000.0 (Q1 2026), $154000.0 (Q4 2025), and $147000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 153,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153,000.00 |
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Sep 30, 2025 | 147,000.00 |
| Sep 30, 2025 | 147,000.00 |
| Jun 30, 2025 | 149,000.00 |
| Jun 30, 2025 | 149,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2024 | 148,000.00 |
| Dec 31, 2024 | 148,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 138,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Dec 31, 2023 | 128,000.00 |
| Dec 31, 2023 | 128,000.00 |
| Sep 30, 2023 | 122,000.00 |
| Sep 30, 2023 | 122,000.00 |
| Jun 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 158,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Sep 30, 2022 | 207,000.00 |
| Sep 30, 2022 | 207,000.00 |
| Jun 30, 2022 | 82,000.00 |
| Jun 30, 2022 | 82,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Dec 31, 2017 | 1,000.00 |
| Dec 31, 2017 | 1,000.00 |
| Sep 30, 2017 | 27,000.00 |
| Sep 30, 2017 | 27,000.00 |
| Jun 30, 2017 | -420,000.00 |
| Jun 30, 2017 | -420,000.00 |
| Mar 31, 2017 | 650,000.00 |
| Mar 31, 2017 | 650,000.00 |
| Sep 30, 2016 | 568,000.00 |
| Sep 30, 2016 | 568,000.00 |
| Jun 30, 2016 | 645,000.00 |
| Jun 30, 2016 | 645,000.00 |
| Mar 31, 2016 | 67,000.00 |
| Mar 31, 2016 | 67,000.00 |